CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
SLIDE-HCC: Phase II trial of STRIDE (durvalumab + tremelimumab) + lenvatinib vs STRIDE in patients with unresectable hepatocellular carcinoma
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Docetaxel and Hormone Treatment compared to Hormone Treatment alone in people with Metastatic Castration Sensitive Prostate Cancer and Less than Optimal PSA Response (TRIPLE-SWITCH)
The inaugural CCTG Award for Excellence in Clinical Trials Conduct will be presented this year at the Recognition Awards at the Annual Spring Meeting of Participants to an individual who exemplifies excellence in clinical trial operations and/or compliance at their institution.
Mark your calendars! Dr Lillian Siu is our guest speaker this year at the Maria Ricci Memorial Lectureship In Oncology taking place at the CCTG Spring Meeting on Saturday April 29, 5:00 pm in the Mountbatten Room at the Chelsea Hotel in Toronto. Dr Siu's lecture is titled "Precision Cancer Medicine Beyond Next Generation Sequencing Gene Panels". This session is RCPSC accredited
About Dr Lillian Siu
Practice changing data presented in endometrial cancer that demonstrates improved progression-free survival outcomes with the addition of Pembrolizumab to chemotherapy for women with advanced or recurrent endometrial cancer.
CCTG is looking for members for our Equity, Diversity, Inclusivity, Indigenization, and Accessibility (EDIIA) Working Groups as part of our EDIIA Action Plan. CCTG strives to create an equitable, diverse, inclusive, accessible, and culturally safe community for our network and for patients.
Canadian Neuroendocrine Tumour Society (CNETS) 2022 Research Grant Award to support Canadian participation in STOPNET international trial. STOPNET is a Randomized Study of Cessation of Somatostatin Analogues after Peptide Receptor Radionuclide Therapy in Mid-Gut Neuroendocrine Tumours.
Update: Non-funded invitations will be sent and request an invitation portal opens at the beginning of March.
If you are planning meetings and/or attending the Spring Meeting be sure to read your invitation carefully so you are clear on the the funding support associated with your invitation.
